Chen Benny J, Cui Xiuyu, Sempowski Gregory D, Chao Nelson J
Departments of Medicine and Immunology, Human Vaccine Institute, Duke University Medical Center, Durham, NC 27705, USA.
Exp Hematol. 2003 Oct;31(10):953-8. doi: 10.1016/s0301-472x(03)00196-6.
To test in a murine model whether recombinant human growth hormone can promote immune recovery after allogeneic T-cell-depleted bone marrow transplantation.
Lethally irradiated (8.5 Gy) BALB/c mice (H2(d)) were transplanted with 5 x 10(6) T cell-depleted bone marrow cells from C57BL/6 mice (H2(b)). Recipient mice were injected intraperitoneally with recombinant human growth hormone (20 microg/dose/day) or saline for the first 4 weeks after transplantation. These animals were followed for phenotypic and functional immune recovery.
Administration of human recombinant growth hormone improved the CD4(+) T-cell counts in peripheral blood on day +14 (44+/-14 vs 33+/-7/microL blood, p<0.05) and day +21 (281+/-109 vs 187+/-76/microL blood, p<0.01) compared with the saline control. These differences were no longer significant by day +28 despite continued growth hormone administration. Similar effects were also observed on CD8(+) T cells and B220(+) B cells. The improvements in peripheral T-cell counts were at least partially as a result of enhanced thymopoiesis because there was an increase in total thymocytes after treatment with growth hormone. T-cell-depleted bone marrow recipients treated with growth hormone rejected the third-party grafts faster than those treated with saline control (median survival time: 20 days vs 26 days, p<0.05).
These data demonstrated that recombinant human growth hormone can accelerate phenotypic and functional immune reconstitution following allogeneic T-cell-depleted bone marrow transplantation in mice.
在小鼠模型中测试重组人生长激素是否能促进去除同种异体T细胞的骨髓移植后的免疫恢复。
对接受8.5 Gy致死性照射的BALB/c小鼠（H2(d)）移植来自C57BL/6小鼠（H2(b)）的5×10⁶个去除T细胞的骨髓细胞。在移植后的前4周，给受体小鼠腹腔注射重组人生长激素（20微克/剂量/天）或生理盐水。对这些动物进行表型和功能免疫恢复的跟踪观察。
与生理盐水对照组相比，注射重组人生长激素使外周血中CD4⁺ T细胞计数在第14天（44±14对33±7/微升血液，p<0.05）和第21天（281±109对187±76/微升血液，p<0.01）有所改善。尽管持续给予生长激素，但到第28天这些差异不再显著。在CD8⁺ T细胞和B220⁺ B细胞上也观察到类似效果。外周T细胞计数的改善至少部分是由于胸腺生成增强，因为用生长激素治疗后总胸腺细胞数量增加。用生长激素治疗的去除T细胞的骨髓移植受体比用生理盐水对照组的受体更快地排斥第三方移植物（中位生存时间：20天对26天，p<0.05）。
这些数据表明重组人生长激素可加速小鼠去除同种异体T细胞的骨髓移植后的表型和功能免疫重建。
